Article thumbnail

Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma

By Timothy J Schaffner and David P Skoner

Abstract

Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least as effective as either fluticasone propionate or budesonide at symptom control, while in many cases having improved safety outcomes and tolerability. The improved safety and comparable efficacy profiles of ciclesonide demonstrated in current studies could potentially yield a treatment option that may lead to improved adherence and outcome

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3048607
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. 2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers.
  2. (2006). A comparative study of inhaled ciclesonide 160 μg/day and fl uticasone propionate 176 μg/day in children with asthma. Pediatr Pulmonol.
  3. A comparison of beclomethasone, salmeterol, and placebo in children with asthma.
  4. (2006). A multinational, 12-week, randomized study comparing the effi cacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther.
  5. a novel inhaled steroid, does not affect hypthalamic-pituitaryadrenal axis function in patients with moderate-to-severe persistent asthma.
  6. A randomized study comparing ciclesonide and fl uticasone propionate in patients with moderate persistent asthma.
  7. and the Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma.
  8. Antiinfl ammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients.
  9. Balancing safety and efficacy in pediatric asthma management.
  10. (1995). Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol.
  11. Ciclesonide – an inhaled corticosteroid prodrug – inhibits allergen induced early and late phase reactions. Eur Respir J. 1998;12(suppl 28):26s. Abstract P0475.
  12. (2007). Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther.
  13. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.
  14. Ciclesonide shows high lung deposition in 2D and 3D-imaging. Am J Respr Crit Care Med.
  15. (2004). Ciclesonide: A novel inhaled corticosteroid for asthma. Drugs Today (Barc).
  16. (2006). Comparable effi cacy of ciclesonide once daily versus fl uticasone propionate twice daily in asthma. Pulm Pharmacol Ther.
  17. (2006). Comparative effi cacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med.
  18. (2007). Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fl uticasone propionate in maintaining control of asthma. Curr Med Res Opin.
  19. (2007). Comparison of the effi cacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr Allergy Immunol.
  20. (2005). Comparison of the effi cacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clin Ther.
  21. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fl uticasone propionate in patients with asthma.
  22. (2008). Comparison of twice-daily inhaled ciclesonide and fl uticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther.
  23. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids.
  24. (2007). Education and Prevention Program. NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma –
  25. Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-infl ammatory activity in vitro. Eur Respir J. 2002;20(suppl 38): Abstract P652.
  26. (2005). Effect of ciclesonide and fl uticasone on hypothalamic-pituitaryadrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol.
  27. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma.
  28. (2004). Effects of hydrofl ouroalkane formulations of ciclesonide 400 μg once daily vs fl uticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharm.
  29. (2005). Effects of inhaled ciclesonide and fl uticasone propionate on cortisol secretion and airway responsiveness to adenosine 5’monophosphate in asthmatic patients. Pulm Pharmacol Ther.
  30. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
  31. (1998). Effi cacy and safety of budesonide inhalation suspension in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol.
  32. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet.
  33. (2005). Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther.
  34. (2007). Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)
  35. (2007). Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2) – the risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol.
  36. (2007). Impact of inhaled corticosteroidinduced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol.
  37. (2004). In vitro and in vivo antiinfl ammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther.
  38. (2007). In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fl uticasone propionate in human lung precision-cut tissue slices. Respir Res.
  39. (2006). In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos.
  40. In vivo epimeric stability of ciclesonide. Am J Respir Crit Care Med. 2003;167:Abstract A1485.
  41. LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women.
  42. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofl ouroalkane metered-dose inhaler compared with budesonide via chlorofl uorocarbon metered-dose inhaler in healthy subjects.
  43. Maintenance of asthma control by once-daily ciclesonide in adults with persistent asthma.
  44. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma.
  45. Once-daily ciclesonide in children: effi cacy and safety in asthma.
  46. (2005). Once-daily ciclesonide is safe and effective in patients with persistent asthma. Respir Med.
  47. (2006). Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol.
  48. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyrylciclesonide in healthy subjects and patients with asthma are similar.
  49. (2004). Pharmacokinetics of [14C]-Ciclesonide after oral administration to healthy subjects. Clin Pharmacokinet.
  50. Population pharmacokinetics and pharmacodynamics of ciclesonide.
  51. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
  52. (2007). Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med.
  53. retention and metabolism of ciclesonide in human alveolar epithelial cells. Eur Respir J. 2005;26(suppl 49):255s.
  54. Salivary IgA and oral candidiasis in asthmatic patients treated with inhaled corticosteroid.
  55. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide.
  56. (2002). Surveillance for asthma – United States 1980–1999. MMWR Surveill Summ.
  57. (2002). The burden of asthma in the United States. Am J Repir Crit Care Med.
  58. The characteristics of bronchial asthma among a young adult population.
  59. (2006). The state of childhood asthma, United States 1980–2005. Advance data from vital and health statistics; no 381, Hyattsville, MD: National Center for Health Statistics.
  60. (2001). Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J.
  61. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur Respir J. 2002;20(suppl 38):Abstract 2579.